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CASE 5 
 
Investigating Suspected Outbreaks of Rare Infectious 
Disease Using Surveillance Data: The CJDSS Perspective 
 
 
Elizabeth Fan, BSc, MPH (MPH Class of 2016) 
Michel Deilgat, BA, MD (Medical Advisor, Public Health Agency of Canada) 
Mark Speechley, PhD (Professor, Western University) 
 
BACKGROUND 
Renée Dubois, a public health nurse consultant of fifteen years, sat at her desk at the Public 
Health Agency of Canada, sipped her tea, and stared out the window. It was a beautiful spring 
morning in Ottawa, Canada. From the corner of her eye, she noticed a red light flashing on her 
landline and listened intently to the voicemails left on the Creutzfeldt-Jakob Disease 
Surveillance System (CJDSS) phone line over the weekend. She listened to the first message, 
then the second, and then the third. As the train of voicemails ended, her eyes widened. For the 
first time in a decade, there had been a suspected outbreak of variant Creutzfeldt-Jakob 
Disease (CJD) in Ontario. 
 
Dr. Lawson, the referring doctor on the last voicemail, sounded calm despite the situation at 
hand. “If you would please call me back as soon as possible, I would like to speak further about 
the next steps.” Dr. Lawson is a neurologist at a well-known neurology center in Toronto, and 
she called regarding a suspicious cluster of possible variant CJD cases in the Greater Toronto 
Area. A set of five patients were displaying early symptoms of rapidly progressive dementia. 
Noting that several of these patients were much younger than the typical age demographic 
prone to sporadic CJD (Exhibit 1), Dr. Lawson immediately contacted the CJDSS to investigate 
these cases as possible cases of variant CJD.  
 
Upon receiving this information, Renée immediately sent out a department-wide email notifying 
the other nurses of the situation. She had previous experience with a possible CJD outbreak a 
decade prior. Luckily, the cases were not variant CJD (as confirmed by autopsy), and were 
instead misdiagnosed cases of sporadic CJD. From this experience, Renée knew that the 
consequences of an outbreak of variant CJD had wide ramifications, which required pre-
planning, inter-sectoral collaboration, and effective mobilization of resources to quickly diagnose 
and isolate the source of a possible outbreak. 
 
CREUTZFELDT-JAKOB DISEASE 
Creutzfeldt-Jakob Disease (CJD) is a rapidly progressing, fatal, neurodegenerative disease. It is 
the human form of bovine spongiform encephalopathy (BSE), popularized as “Mad Cow 
Disease” in the early 2000s. The worldwide incidence of CJD is approximately one to two cases 
per 1,000,000 persons (NCJDRSU, 2016). In Canada, this translates to 40-50 new cases per 
year (Exhibit 2). Since 1994, there have been over 800 cases of confirmed CJD in Canada 
(Exhibit 3), with a majority of cases in Ontario and Quebec (Exhibit 4). 
 
DISEASE SYMPTOMOLOGY AND PROGRESSION 
Creutzfeldt-Jakob Disease is characterized by the accumulation of prion proteins in the brain 
and neural tissue degeneration, which gives the tissue a spongy appearance (PHAC, 2012).  
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At onset, patients often experience psychiatric or sensory symptoms, including anxiety, 
depression, visual hallucinations, and aphasia (WHO, 2012). As the disease rapidly progresses, 
neurological defects develop within weeks, resulting in involuntary movements, dementia, and 
ataxia (UCSF, 2016). The average duration of illness, from initial neurological symptoms to 
death, can vary from four to 40 months (Kovács et al., 2005). At time of death, patients are 
completely immobile and mute (WHO, 2012). 
 
TYPES OF CJD 
There are three types of CJD: sporadic, genetic, and acquired. In ~85% of patients, the disease 
occurs sporadically, without any known external source of infection. This is referred to as 
sporadic CJD. In 10% to 15% of patients, CJD develops in familial clusters, passed down 
through inherited mutations of the prion protein gene PRNP. This type of CJD is referred to as 
genetic CJD. Lastly, acquired CJD can develop in several ways and is the rarest form of CJD, 
occurring in approximately 1% of patients. Acquired CJD is an umbrella term used to describe 
iatrogenic CJD and variant CJD. As the name suggests, iatrogenic CJD is transmitted 
iatrogenically, induced accidentally via hospital or diagnostic procedures. Iatrogenic CJD is 
linked with exposure to contaminated hormones, infected dura mater or corneal grafts, and 
contaminated neurosurgical instruments. However, variant CJD (vCJD) develops from the 
ingestion of BSE-contaminated meats, or blood transfusions from a vCJD-positive donor (WHO, 
2012; Budka & Will, 2015). WHO’s case definitions of CJD are presented in Exhibit 5. 
 
PRIONS AS INFECTIOUS AGENTS  
The prion protein (PrP) in its normal form is present in all humans and animals (WHO, 2011). 
However, PrP is in an altered, self-propagating form in diseases like CJD and is referred to as a 
prion or a proteinaceous infectious particle (Prusiner, 1998). When PrP is in its mutated form, it 
is able to infect non-mutated forms of the protein, resulting in a cascade effect in the brain. 
Contact with tiny amounts of prion-contaminated material can initiate the disease process in an 
otherwise healthy individual. Once they appear, abnormal prion proteins aggregate. The 
aggregation of proteins contributes to widespread neuron loss. However, the exact molecular 
mechanism of this process is unknown (Clarke et al., 2001).  
 
The altered form of PrP is responsible for a host of diseases including Kuru, Gerstmann–
Sträussler–Scheinker syndrome, and fatal familial insomnia (Will, 2003), with the latter two 
implicated in genetic routes of transmission (Collins et al., 2001).  
 
Certain surgical procedures can transmit prions. These include dura mater grafts, corneal grafts, 
and any surgery involving neural tissues (PHAC, 2007). Prions can also be spread via exposure 
to BSE-containing foods. However, there is no evidence that CJD can spread via social contact, 
sexual contact, mother-to-child, blood transfusion, or through routine health care (PHAC, 2007). 
CJD tissue infectivity is outlined in Exhibit 6.  
 
A HISTORY OF VARIANT CJD IN CANADA AND WORLDWIDE 
The earliest cases of vCJD were identified in 1994 in unexpectedly young individuals in the 
United Kingdom (Will et al., 1996). Since then, over 200 cases of vCJD have been identified 
worldwide, with 175 cases in the UK alone and 49 cases in other countries around the world – 
including two in Canadian residents (WHO, 2012). 
 
After 1996, the United Kingdom implemented strict food safety measures to prevent further 
contamination in its food supply. Canada followed suit after the first Canadian case of vCJD was 
identified in 2002 (Jansen et al., 2003).  
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Furthermore, scientists discovered that several patients in the UK were infected with vCJD-
positive blood via blood transfusion (Belay & Schonberger, 2005; WHO, 2008). This revelation 
spurred many countries to take preventive measures to regulate their blood supplies and to 
minimize the risk of vCJD being spread by blood transfusion. This remains true even today, as 
Canadian Blood Services and Héma-Québec ensure that blood donations are not accepted 
from individuals who may be silent carriers of CJD – for example, individuals who may have 
lived a cumulative of three or more months in the United Kingdom between 1980 and 1996, or 
five or more years in Western Europe from 1980 to 2007 (Héma-Québec, 2014).  
 
Currently, the Government of Canada regulates the Canadian beef industry to minimize the risk 
of BSE contamination. It has also minimized the risk of infection through surgical procedures 
(PHAC, 2007) and through blood transfusion (Héma-Québec, 2014). By implementing various 
infection-control guidelines, as outlined in the Creutzfeldt-Jakob Disease Quick Reference 
Guide (PHAC, 2007), the risk of BSE infection in Canada is considered to be extremely low.  
 
CREUTZFELDT-JAKOB DISEASE SURVEILLANCE 
The Canadian Creutzfeldt-Jakob Disease Surveillance System (CJDSS) was established by 
Health Canada in 1998 (PHAC, 2003), in response to the widespread outbreak of vCJD in the 
United Kingdom. It was created as a national surveillance system for Creutzfeldt-Jakob 
Disease. Currently, the role of the CJDSS is to assist in the investigation and diagnosis of 
suspected cases of CJD in Canada, provide support to patients and health care providers, and 
ultimately protect the health of Canadians by reducing the risk of CJD transmission.  
 
Following the World Health Organization’s (WHO) model for comprehensive surveillance of 
human prion diseases, the CJDSS offers support to collaborating health care professionals. 
This is completed via initial consultation, referral for laboratory testing, provision of logistic 
support, education, and awareness. With informed consent from patients, a detailed medical 
chart review and family interviews are also completed. The resultant diagnostic and 
epidemiological information gathered by the CJDSS is assembled in a comprehensive online 
database and is used to support further epidemiological analysis and public health decision-
making (PHAC, 2016). 
 
HOW IS CJD DIAGNOSED? 
Currently, there is no single definitive diagnostic test for CJD. However, if a patient is exhibiting 
symptoms of CJD, there are several recommended laboratory tests that can be completed to 
rule out more common causes of dementia or neurological symptoms, including encephalitis or 
chronic meningitis (NINDS, 2003). Recommended laboratory testing for CJD is outlined in 
Exhibit 7. 
 
PUBLIC HEALTH CHALLENGES OF PRION DISEASES 
Prion diseases like CJD pose a unique combination of challenges to public health. These 
include their long incubation periods (upwards of a decade), a lack of host immunity, a strong 
resistance to decontamination (for example, in neurosurgical instruments), limited diagnostic 
testing, and potential for zoonotic and health care-based transmission (Coulthart et al., 2015).  
 
Because the early symptoms of CJD are often non-specific, and the disease itself is quite rare, it 
can be very difficult for physicians to diagnose. The disease also progresses quickly, and it can 
be difficult for physicians to support families through the quick deterioration of their loved one. 
Thus, it is important for public health to be aware of CJD and its risks and to be able to mobilize 
resources to isolate and quarantine the source of a possible outbreak situation. 
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BACK TO RENÉE – THE CASES AT HAND  
After conducting an initial intake questionnaire with physicians and health care providers, Renée 
amalgamated essential information regarding the five cases of suspected CJD, taking care to 
note that all cases occurred within 50 km of Toronto. She recorded the patients’ dates of birth, 
dates of onset, symptoms, and test results. She also noted rapidity of symptom progression.  
 
Some initial test results are recorded in Exhibit 8. However, due to the varied availability of 
equipment and quality of care experienced by Ontarians, not all recommended diagnostic tests 
were completed prior to patient death (as in Case #3), while some results are still pending 
(Case #4 and #5). 
 
MASS MEDIA GETS THE SCOOP 
Two weeks after Renée received the first voicemail from Dr. Lawson, Renée received word from 
Dr. Lawson that the first patient of the five patients passed away. Mr. C. (Case #2) was a young, 
prolific athlete, who was set to compete in the upcoming Olympics in Brazil. His rapidly declining 
health was covered extensively in the public eye, with frequent posts to social media outlining 
his deteriorating physical state.  
 
Local reporters had begun flooding the neurology clinics and hospitals frequented by Mr. C., 
demanding answers. Several news outlets also released articles sensationalizing the potential 
return of “Mad Cow Disease,” and imploring the federal government to intervene in the 
investigation. Lobbyists began to spread sensationalized articles demanding a beef ban, and 
Health Canada was being pressured to release a statement. 
 
DEVELOPING AN INVESTIGATIVE STRATEGY: RENÉE’S DECISION 
Renée tasked two nurses to compile the medical records and clinical information for each case. 
Knowing the causes and methods of transmission of CJD, Renée struggled to come up with the 
root cause of this outbreak. Without access to each patient’s medical history, she was struggling 
to weave a connecting thread between the individual cases. 
 
Renée needed to figure out the best course of action to lead the team of nurses to the correct 
diagnosis. From her previous experiences working in a neurology clinic for 10 years, she was 
very familiar with CJD diagnostic tests and how to interpret them. What were the best diagnostic 
tests for her to pursue? What were some potential root causes she could suggest the team to 
concentrate on to direct their investigation? Were these cases connected? If so, what should 
she do next? 
 
A confident speaker, Renée often presented about CJD at universities and conferences across 
Canada. From her experiences as a keynote speaker, Renée knew that referring to CJD as 
“Mad Cow Disease” would merely fan the flames of public hysteria. Reducing the 
sensationalized stories in the media was her first goal. 
  
In the case of Mr. C., what essential information should Renée recommend that the hospitals 
and neurology clinics share to the media? What should Renée’s main message be? Who should 
Renée collaborate with to get her message out to the public? What cautionary information 
should the public campaign include? 
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EXHIBIT 1 
Distribution of Variant and Sporadic CJD Cases in the UK, by Age 
 
 
Source: Will, 2003. Reproduced with permission from Robert G. Will. Acquired Prion Disease: Iatrogenic 
CJD, Variant CJD, Kuru. British Medical Bulletin (2003) 66 (1): 255-265. Published by Oxford 
University Press online at: https://academic.oup.com/bmb/article/66/1/255/284826/Acquired-
prion-disease-iatrogenic-CJD-variant-CJD?searchresult=1 For permissions please email: 
journals.permissions@oup.com. 
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EXHIBIT 2 
Incidences of CJD in Canada: 1999-2016 
As of June 30, 2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: PHAC, 2016. 
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EXHIBIT 3 
CJD Deaths Reported by the CJD Surveillance System (1994-2016) 
As of June 30, 2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: PHAC, 2016. 
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EXHIBIT 4 
Map of CJD Cases in Canada 
As of June 30, 2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: PHAC, 2016. 
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EXHIBIT 5 
Case Definitions of CJD 
 
At time of death, all possible CJD cases in Canada are classified according to the WHO 
diagnostic criteria for CJD: 
 
Definite CJD 
- Requires neuropathologic examination 
- Confirmed by cranial autopsy 
 
Probable CJD 
- Case is lacking neuropathologic examination 
- Based on combination of non-neuropathologic criteria: 
 Clinical profile (ataxia, rapid progressive dementia, etc.) 
 Results of cerebrospinal fluid (CSF) protein immunoassays 
 EEG 
 MRI 
 Genetic analysis 
 Brain/tonsil biopsy 
 
Possible CJD 
- Information is even more limited. 
 
 
Source: WHO, 2008. 
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EXHIBIT 6 
CJD Tissue Infectivity 
 
High Infectivity Low Infectivity 
‐ Brain 
‐ Cerebrospinal fluid 
‐ Dura mater 
‐ Pituitary gland 
‐ Posterior eye 
‐ Spinal cord and ganglia 
‐ Trigeminal ganglia 
‐ Cornea 
‐ Kidney 
‐ Liver 
‐ Lung 
‐ Lymph nodes 
‐ Placenta 
‐ Spleen 
No Detected Infectivity 
‐ Adipose tissue 
‐ Adrenal gland 
‐ Appendix 
‐ Blood (including cord blood) 
‐ Blood vessels 
‐ Bone marrow 
‐ Breast milk 
‐ Dental pulp 
‐ Epididymis 
‐ Esophagus 
‐ Feces 
‐ Gingival tissue 
‐ Heart 
‐ Ileum 
‐ Jejunum 
‐ Large intestine 
‐ Nasal mucosa 
‐ Nasal mucous 
‐ Ovary 
‐ Pancreas 
‐ Pericardium 
‐ Peripheral nerves 
‐ Placental fluids 
‐ Prostate 
‐ Saliva 
‐ Semen 
‐ Seminal vesicle 
‐ Skeletal muscle 
‐ Skin 
‐ Sweat 
‐ Tears 
‐ Testis 
‐ Thymus 
‐ Thyroid gland 
‐ Tongue 
‐ Tonsil 
‐ Trachea 
‐ Urine  
 
Source: PHAC, 2007. 
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EXHIBIT 7 
Recommended Laboratory Testing for CJD 
 
Upon initial intake of a patient, it is recommended that the following tests be conducted in order 
to confirm or rule-out the possibility of CJD: 
 
1. CEREBROSPINAL FLUID (CSF) TESTING 
In all cases of CJD, CSF testing is highly recommended. CSF is collected via lumbar 
puncture and is tested for levels of various proteins. Some protein tests that are conducted 
using CSF include 14-3-3, S100B, and tau protein tests (Coulthart et al., 2011). Elevated 
levels of these proteins have been reported to support a CJD diagnosis. However, each test 
has varying levels of sensitivity and specificity, and the threshold limits of each protein can 
differ from patient to patient. Currently, CSF tau shows the best overall diagnostic accuracy, 
compared to 14-3-3 or S100B protein markers (Coulthart et al., 2011).  
 
2. COMPUTERIZED TOMOGRAPHY (CT) SCANS 
Computerized tomography (CT) scans of the brain can sometimes rule out the possibility 
that exhibited symptoms may have resulted from another neurological issue including 
strokes or tumours in the brain (WHO, 2008).  
 
3. ELECTROENCEPHALOGRAPHY (EEG) 
Electroencephalography (EEG) measures waves of electrical activity in the brain. This test 
can be valuable as certain sharp wave complexes are characteristic in sporadic CJD. 
However, EEG is not useful in the diagnosis of vCJD (WHO, 2008).  
 
4. MAGNETIC RESONANCE IMAGING (MRI) 
Magnetic resonance imaging (MRI) brain scans also can reveal characteristic patterns of 
brain degeneration that can help diagnose CJD (WHO, 2008). 
 
5. GENETIC TESTING 
Blood samples can be used to prepare DNA for genetic analysis. Specific mutations in the 
PRNP gene, including P102L, E200K and D178, are CJD-causing variations. However, 
some variations are silent, and do not cause disease – for example, M129V (Swietnicki et 
al., 1998). 
 
6. TONSIL BIOPSY 
Prion proteins can often be found in tonsil tissues in CJD-positive patients. However, this 
test is not useful in diagnosing sporadic or genetic CJD (WHO, 2008). 
 
7. BRAIN AUTOPSY 
While the results of the aforementioned six diagnostic tests may lead to a strong diagnosis 
of CJD, the only definite method of knowing whether the patient has CJD is through brain 
autopsy at time of death. However, autopsy is a lengthy process, requiring several months 
to complete. Some characteristic changes in a CJD-positive brain include: 
 Spongiform change 
 Loss of neurons 
 High astrocyte density 
 Presence of abnormal prion proteins 
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EXHIBIT 8 
Case Characteristics and Test Results 
 
Case # Age at Onset CSF Results EEG MRI Status
1 42 Positive Negative Negative Alive 
2 25 Positive Negative Positive Dead 
3 33 Pending Unknown Unknown Dead 
4 44 Positive Negative Pending Dead 
5 36 Pending Negative Pending Alive 
 
Source: Created by author. 
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BACKGROUND 
A suspected cluster of variant Creutzfeldt-Jakob Disease (CJD) cases (a fatal 
neurodegenerative disease) has been identified in Toronto. Renée Dubois, a public health 
nurse, must utilize epidemiological data to recognize the outbreak, and mobilize resources to 
support patients and health care providers. The assembled epidemiological information 
gathered by the CJD surveillance system must be used to further support data analysis, public 
health decision-making, and public messaging. This case may be used to supplement lectures 
covering relevant public health events or epidemic analysis.  
 
OBJECTIVES 
1. Understand the importance of case reporting and laboratory data for surveillance of 
infectious diseases and outbreak detection. 
2. Identify limitations of diagnostic tests and laboratory data, as well as the importance of 
ethical guidelines and informed consent in patient sampling. 
3. Devise an emergency preparedness management strategy in the event of a communicable 
disease outbreak. 
4. Interpret epidemiological data to understand the spread, origin, and effects of communicable 
disease. 
5. Interpret laboratory data in context of epidemiological data in order to make 
recommendations for timely public health action. 
 
DISCUSSION QUESTIONS 
1. What is an outbreak? 
a. What are some modern examples of outbreaks? 
2. How can you recognize an outbreak? 
3. What sources of information would you consult to confirm that it is an outbreak? 
a. How would you access this information? 
b. What are the limitations of diagnostic tests and laboratory data? 
4. What information is most relevant for public health decision-making? 
5. What is the role of media in outbreak investigation and communication? 
a. How do you ensure confidentiality in a high profile outbreak? 
b. What is the public message you would communicate, and what would that look like? 
 Relate this to current public health events. 
 
KEYWORDS 
Epidemiology; Creutzfeldt-Jakob Disease (CJD); outbreak management; surveillance data; 
PHAC. 
